Lupus erythematosus

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| Lupus erythematosus | |
|---|---|
| Synonyms | |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Fatigue (medical), joint pain, rash, fever |
| Complications | Kidney failure, heart disease, lung disease |
| Onset | Usually between ages 15 and 45 |
| Duration | Long term |
| Types | N/A |
| Causes | Autoimmune disease |
| Risks | Genetics, environmental factors, hormonal factors |
| Diagnosis | Blood test, urinalysis, biopsy |
| Differential diagnosis | Rheumatoid arthritis, fibromyalgia, multiple sclerosis |
| Prevention | N/A |
| Treatment | Immunosuppressive drug, corticosteroids, antimalarial medication |
| Medication | Hydroxychloroquine, methotrexate, prednisone |
| Prognosis | Variable; improved with treatment |
| Frequency | 20 to 70 per 100,000 people |
| Deaths | |
Lupus erythematosus (LE) is a chronic, multi-systemic autoimmune disease that causes the body's immune system to mistakenly attack healthy cells and tissues. It encompasses a range of clinical entities, the most common forms being systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).

Classification[edit]
- Lupus erythematosus can be classified into several types, each with unique clinical characteristics:
- Systemic Lupus Erythematosus (SLE): This is the most common and severe form of LE, affecting multiple organ systems in the body.
- Cutaneous Lupus Erythematosus (CLE): This form predominantly affects the skin, with three main subtypes: acute, subacute, and chronic.
- Drug-induced Lupus Erythematosus (DILE): This is a drug-induced autoimmune condition that typically resolves once the causative drug is discontinued.
- Neonatal Lupus Erythematosus (NLE): This is a rare condition affecting newborns, caused by the transplacental passage of maternal autoantibodies.

Pathophysiology[edit]
Although the precise cause of LE is unknown, it's considered a multifactorial disease involving genetic, hormonal, environmental, and immunological factors. At the cellular level, it's characterized by the production of a broad array of autoantibodies, most notably antinuclear antibodies (ANA), leading to immune complex formation and inflammation.
Clinical Manifestations[edit]
Clinical features of LE can vary significantly between individuals, making it a challenging condition to diagnose. Common symptoms include fatigue, joint pain, and skin rashes — particularly the classic "butterfly rash" over the cheeks and bridge of the nose. More severe manifestations can involve the heart, lungs, kidneys, and nervous system.
Diagnosis[edit]
Diagnosis of LE involves a combination of clinical findings and laboratory tests. These may include complete blood count (CBC), urinalysis, and autoantibody tests such as ANA, anti-dsDNA, anti-Sm, and antiphospholipid antibodies. Diagnostic criteria have been developed by the American College of Rheumatology (ACR) and the Systemic Lupus International Collaborating Clinics (SLICC) to assist in the diagnosis of SLE.
Treatment[edit]
Management of LE is tailored to the individual's symptoms and organ involvement. Non-steroidal anti-inflammatory drugs (NSAIDs) and antimalarials like hydroxychloroquine are often used to manage mild disease. In moderate to severe disease, corticosteroids and immunosuppressive agents may be required.
Prognosis[edit]
The prognosis of LE depends on various factors, including the severity of disease, organs involved, and the individual's response to treatment. With appropriate treatment and management of symptoms, many individuals with LE can lead full and active lives.
See Also[edit]
- Autoimmune diseases
- Systemic Lupus Erythematosus
- Cutaneous Lupus Erythematosus
- Drug-induced Lupus Erythematosus
- Neonatal Lupus Erythematosus
References[edit]
- D'Cruz DP, Khamashta MA, Hughes GR. (2007). Systemic lupus erythematosus. The Lancet, 369(9561), 587-596.
- Petri M, Orbai AM, Alarcón GS, et al. (2012). Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus
|
|
|
| Urticaria and erythema | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian


